A phase II study of Avelumab in combination with Axitinib in patients with advanced Thymic epithelial tumours (TET) Studio interventistico, multicentrico, in aperto, non randomizzato di fase II con Avelumab in combinazione con Axitinib in pazienti con carcinomi timici in stadio avanzato.

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 15 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avelumab (Primary) ; Axitinib (Primary)
Indications Carcinoma; Malignant thymoma; Thymoma
Focus Therapeutic Use
Acronyms CAVEATT

Most Recent Events

09 Sep 2022 Status changed from recruiting to active, no longer recruiting, as per Results published in the Lancet Oncology
09 Sep 2022 Results published in the Lancet Oncology
10 Jun 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight